Eris Lifesciences reported 16.2% rise in consolidated net profit to Rs 107.7 crore on 16% increase in net sales to Rs 325.27 crore in Q2 FY21 over Q2 FY20.
Profit before tax (PBT) in Q2 September 2020 stood at Rs 115.84 crore, up by 12.7% from Rs 102.77 crore in Q2 September 2019. Tax expense during the quarter declined 19.4% year-on-year (YoY) to Rs 81 crore.
EBITDA rose 13.6% to Rs 124.80 crore in Q2 FY21 from Rs 109.80 crore in Q2 FY20. EBITDA margin stood at 37.8% as on 30 September 2020 as against 38.6% as on 30 September 2019.
Eris Lifesciences is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian pharmaceutical market.
The scrip fell 2.65% to Rs 504.45 on the BSE. It traded in the range of 502.50 and 517.50 so far during the day.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU